Cell Therapy Manufacturing Market Size & Competitors

The cell therapy manufacturing market is valued at USD 4.90 billion in 2024 growing at a CAGR of 9.90% during the forecast period 2024-2035.

Currently, over 300 cell therapies are in various stages of clinical development, with more than 1,930 clinical studies initiated since 2019 focusing on these candidates. Several of these commercialized cell therapies have emerged as top-selling drugs in the healthcare sector. For example, Gilead Sciences reported that Yescarta® achieved sales exceeding USD 1.5 billion, while Tecartus® generated sales of USD 370 million in 2023.

Given the substantial evidence supporting the clinical benefits and therapeutic potential of cell therapies, stakeholders are now concentrating on optimizing the manufacturing processes for these therapies. In recent years, numerous advanced automation technologies and platforms have been developed, demonstrating the potential to significantly lower manufacturing costs, thus making these products more affordable. One notable innovation, GMP-In-A Box, offers several advantages, including increased throughput, reduced idle time between batch runs, and decreased manual labor. However, the overall automation process faces challenges due to the complex steps involved in cell therapy manufacturing. Additionally, the lack of specialized infrastructure and trained personnel in this field poses significant obstacles to the growth of this segment.

Key Market Segments

Type of Cell Therapy

T Cell Therapies
NK Cell Therapies
Dendritic Cell Therapies
Stem Cell Therapies

Source of Cells

Autologous
Allogeneic
Unspecified

Scale of Operation

Clinical
Commercial

Type of Manufacturer

In-house Manufacturing
Contract Manufacturing Organization

Geography

North America
Europe
Asia-Pacific
Rest of the World

Research Coverage:

A general introduction to cell therapies, along with information on the key challenges and factors influencing the cell therapy manufacturing market. It provides details on the automation tools and technologies being utilized for improving manufacturing processes and the future prospects in this domain.
An overview of the current market landscape with respect to the industry players engaged in the manufacturing of cell-based therapies. It features information on their company size, year of establishment, location of headquarters, location of manufacturing facilities, type of manufacturer (in-house manufacturers and contract manufacturing organizations), type of cell manufactured (immune cells, stem cells and others), source of cells (autologous and allogeneic), scale of operation (preclinical, clinical and commercial) and additional services offered (research and development, cell culture development, cell banking, documentation, testing, packaging, supply chain management and regulatory support).
An overview of the current cell therapy manufacturing market landscape with respect to the non-industry players engaged in the manufacturing of cell-based therapies. It features information on their year of establishment, location of headquarters, location of manufacturing facilities, type of manufacturer (in-house manufacturers and contract manufacturing organizations), type of cell manufactured (immune cells, stem cells and others), source of cells (autologous and allogeneic), scale of operation (preclinical, clinical and commercial) and additional services offered (research and development, cell culture development, cell banking, documentation, testing, packaging, supply chain management and regulatory support).
A discussion on cell therapy manufacturing related regulations across various geographies, including North America (focusing on the US), Europe and Asia (focusing on Japan and China), featuring an analysis of the diverse certifications / accreditations awarded to the manufacturing facilities by important regulatory bodies across the globe.
An overview of the several roadmaps published by different agencies across the globe in order to provide strategies to advance cell therapy manufacturing process.
An elaborate discussion on the role of technology automation in cell therapy manufacturing in order to optimize the current manufacturing practices with the use of closed and single use systems. Further, it features a roadmap that provides information on the steps to develop automation devices, supported by two case studies. It also presents a qualitive analysis on the cost incurred while manufacturing cell-based therapies using manual versus automated manufacturing approaches. In addition, it features a list of organizations that offer automated technologies for manufacturing operations or provide services to therapy developers to automate their cell therapy production process.
Elaborate profiles of industry players involved in cell therapy manufacturing. Each profile features a brief overview of the company, along with details related to its service portfolio, its manufacturing capabilities and facilities, recent developments and an informed future outlook.
Elaborate profiles of non-industry players involved in cell therapy manufacturing, featuring an overview of the organization, along with details related to their service portfolio and manufacturing facilities.
A discussion on non-profit organizations in cell therapy manufacturing, featuring a list of organizations that are actively involved in the development and production of cell-based therapies, across different geographical locations, along with information on various international / national societies that help in disseminating knowledge about the advancement of these therapies to the general community.
An analysis of completed, ongoing and planned clinical trial, based on several relevant parameters, such as trial registration year, enrolled patient population, trial status, trial phase, type of sponsor / collaborator, patient segment, study design, most active players (in terms of number of clinical trials conducted) and geographical distribution of trials.
A detailed analysis of the recent partnerships and collaborations inked by players focused on the manufacturing of cell-based therapies, since 2016, based on several relevant parameters, such as the year of partnership, type of partnership, type of cells manufactured, scale of operation, most active players (in terms of number of partnerships) and geographical distribution.
An analysis of the various expansion initiatives undertaken by service providers engaged in this domain in order to augment their respective cell therapy manufacturing capabilities, during the period 2017-2024, based on several relevant parameters, such as year of expansion, type of expansion, type of cell manufactured, scale of operation, location of expanded manufacturing facility, and most active players (in terms of number of expansion initiatives undertaken).
An in-depth analysis of the various cell therapy manufacturing focused initiatives undertaken by big pharma players, based on several relevant parameters, such as number of initiatives, year of initiative, purpose of initiative, type of initiative, scale of operation and type of cell manufactured.
An estimate of the overall, installed capacity for the manufacturing of cell-based therapies, based on information reported by various industry and non-industry stakeholders in the public domain, highlighting the distribution of the available capacity (in terms of cleanroom area and number of cleanrooms) on the basis of scale of operation (preclinical, clinical and commercial), and key geographical regions (North America, Europe, Asia Pacific and Rest of the World).
Informed estimates of the annual commercial and clinical demand for cell therapies (in terms of number of patients), based on type of cell therapy and key geographical regions.
A detailed analysis of various factors that are likely to influence the price of cell-based therapies, featuring different models / approaches adopted by manufacturers in order to determine the price of their proprietary offerings.
A qualitative analysis that highlights the various factors that need to be taken into consideration by cell therapy developers, while deciding whether to manufacture their respective products in-house or engage the services of a CMO.
A detailed total cost of ownership analysis based on company size, for cell therapy manufacturing organizations, over a period of 20 years.
A detailed cell therapy manufacturing market forecast analysis in order to estimate the existing market size and future opportunity over the next decade. Based on multiple parameters, such as number of ongoing / planned clinical studies, cell therapy manufacturing costs, target patient population, and anticipated adoption of such therapies, we have provided informed estimates on the evolution of the market in the short to mid-term and mid to long-term, for the forecast period 2024-2035. The report also features the likely distribution of the current and forecasted opportunity within the market. Further, in order to account for future uncertainties and to add robustness to our model, we have provided three forecast scenarios, namely conservative, base and optimistic scenarios, representing different tracks of the industry’s growth.
Detailed projections of the current and future cell therapy manufacturing market across different types of cell therapy, such as T cell therapies, NK cell therapies, dendritic cell therapies, and stem cell therapies.
Detailed projections of the current and future cell therapy manufacturing industry across different sources of cell, such as autologous, allogeneic and unspecified.
Detailed projections of the current and future cell therapy manufacturing market across different scales of operation, such as clinical and commercial.
Detailed projections of the current and future cell therapy manufacturing revenue across different types of manufacturers, such as in-house manufacturers and contract manufacturing organizations.
Detailed projections of the current and future cell therapy manufacturing market across various geographies, such as North America, Europe, Asia Pacific, and Rest of the World.
A discussion on affiliated trends, key drivers and challenges, which are likely to impact the industry’s evolution, under an elaborate SWOT framework, along with a Harvey ball analysis, highlighting the relative effect of each SWOT parameter on the overall market dynamics.
Insights generated in a market-wide survey, featuring inputs solicited from experts who are directly / indirectly involved in the development and / or manufacturing of cell-based therapies.

Key Benefits of Buying this Report

The report offers market leaders and newcomers valuable insights into revenue estimations for both the overall market and its sub-segments.
Stakeholders can utilize the report to enhance their understanding of the competitive landscape, allowing for improved business positioning and more effective go-to-market strategies.
The report provides stakeholders with a pulse on the Cell Therapy Manufacturing Market, furnishing them with essential information on significant market drivers, barriers, opportunities, and challenges.

Leading Market Companies

AGC Biologics
BioNTech Innovative Manufacturing Services
Cell and Gene Therapy Catapult
Cell Therapies
Center for Cell and Gene Therapy, Baylor College of Medicine
Centre for Cell Manufacturing Ireland, National University of Ireland
Charles River Laboratories
Clinical Cell and Vaccine Production Facility, University of Pennsylvania
FUJIFILM Cellular Dynamics
Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
KBI Biopharma
Laboratory for Cell and Gene Medicine, Stanford University
Lonza
MEDINET
Minaris Regenerative Medicine
Molecular and Cellular Therapeutics, University of Minnesota
Newcastle Cellular Therapies Facility, Newcastle University
Nikon CeLL Innovation
Rayne Cell Therapy Suite, King’s College London
RoslinCT
Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
Sydney Cell and Gene Therapy
Thermo Fisher Scientific
WuXi AppTec

1. PREFACE

1.1. Introduction
1.2. Market Share Insights
1.3. Key Market Insights
1.4. Report Coverage
1.5. Key Questions Answered
1.6. Chapter Outlines

2. RESEARCH METHODOLOGY

2.1. Chapter Overview
2.2. Research Assumptions
2.3. Project Methodology
2.4. Forecast Methodology
2.5. Robust Quality Control
2.6. Key Market Segmentations
2.7. Key Considerations
2.7.1. Demographics
2.7.2. Economic Factors
2.7.3. Government Regulations
2.7.4. Supply Chain
2.7.5. COVID Impact / Related Factors
2.7.6. Market Access
2.7.7. Healthcare Policies
2.7.8. Industry Consolidation

3. ECONOMIC AND OTHER PROJECT SPECIFIC CONSIDERATIONS

3.1. Chapter Overview
3.2. Market Dynamics
3.2.1. Time Period
3.2.1.1. Historical Trends
3.2.1.2. Current and Forecasted Estimates
3.2.2. Currency Coverage
3.2.2.1. Overview of Major Currencies Affecting the Market
3.2.2.2. Impact of Currency Fluctuations on the Industry

3.2.3. Foreign Exchange Impact
3.2.3.1. Evaluation of Foreign Exchange Rates and their Impact on Market
3.2.3.2. Strategies for Mitigating Foreign Exchange Risk

3.2.4. Recession
3.2.4.1. Historical Trends Analysis of Past Recessions and Lessons Learnt
3.2.4.2. Assessment of Current Economic Conditions and Potential Impact on the Market

3.2.5. Inflation
3.2.5.1. Measurement and Analysis of Inflationary Pressures in the Economy
3.2.5.2. Potential Impact of Inflation on the Market Evolution

4. EXECUTIVE SUMMARY

5. INTRODUCTION

5.1. Chapter Overview
5.2. Introduction to Cell-based Therapies
5.2.1. Comparison of Cell-based Therapies and Other Biotechnological Products
5.2.2. Classification of Advanced Therapy Medicinal Products (ATMPs)
5.2.3. Current Market Landscape of ATMPs
5.3. Overview of Cell Therapy Manufacturing

5.4. Cell Therapy Manufacturing Models
5.4.1. Centralized Manufacturing
5.4.2. Decentralized Manufacturing

5.5. Scalability of Cell Therapy Manufacturing Processes
5.5.1. Scale-up
5.5.2. Scale-out

5.6. Types of Cell Therapy Manufacturers

5.7. Key Challenges for Manufacturing Cell Therapies

5.8. Key Factors Influencing Cell Therapy Manufacturing
5.8.1. Characterization
5.8.2. Cost of Goods

5.9. Automation of Cell Therapy Manufacturing Processes
5.10. Cell Therapy Manufacturing Supply Chain
5.11. Future Perspectives

6. CELL THERAPY MANUFACTURERS (INDUSTRY PLAYERS): MARKET LANDSCAPE

6.1. Chapter Overview
6.2. Industry Players: Overall Market Landscape
6.2.1. Analysis by Year of Establishment
6.2.2. Analysis by Company Size
6.2.3. Analysis by Location of Headquarters
6.2.4. Analysis by Company Size and Location of Headquarters
6.2.5. Analysis by Location of Manufacturing Facility
6.2.6. Analysis by Type of Manufacturer
6.2.7. Analysis by Location of Headquarters and Type of Manufacturer
6.2.8. Analysis by Type of Cell Manufactured
6.2.9. Analysis by Location of Headquarters and Type of Cell Manufactured
6.2.10. Analysis by Source of Cells
6.2.11. Analysis by Type of Cell Manufactured and Source of Cells
6.2.12. Analysis by Scale of Operation
6.2.13. Analysis by Additional Services Offered
6.2.14. Analysis by Company Size and Additional Services Offered

7. CELL THERAPY MANUFACTURERS (NON-INDUSTRY PLAYERS): MARKET LANDSCAPE

7.1. Chapter Overview
7.2. Non-Industry Players: Overall Market Landscape
7.2.1. Analysis by Year of Establishment
7.2.2. Analysis by Location of Headquarters
7.2.3. Analysis by Location of Manufacturing Facility
7.2.4. Analysis by Type of Manufacturer
7.2.5. Analysis by Location of Headquarters and Type of Manufacturer
7.2.6. Analysis by Type of Cell Manufactured
7.2.7. Analysis by Location of Headquarters and Type of Cell Manufactured
7.2.8. Analysis by Source of Cells
7.2.9. Analysis by Type of Cell Manufactured and Source of Cells
7.2.10. Analysis by Scale of Operation
7.2.11. Analysis by Additional Services Offered

8. REGULATORY LANDSCAPE

8.1. Chapter Overview
8.2. Current Scenario
8.2.1. Regulatory Guidelines in North America
8.2.2. Regulatory Guidelines in Europe
8.2.3. Regulatory Guidelines in Asia Pacific
8.2.3.1. Regulatory Guidelines in Japan
8.2.3.2. Regulatory Guidelines in China
8.2.4. Conditional Approvals

8.3. Regulatory Authorities for Cell Therapy Manufacturing
8.3.1. Cell Therapy Manufacturing (Industry Players): Regulatory Authorities

8.4. Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
8.5. Existing Challenges to Early-Stage Manufacturing of Cell Therapies
8.6. Variability in Regulatory Guidelines across Different Geographies

9. ROADMAPS FOR OVERCOMING CHALLENGES

9.1. Chapter Overview
9.2. Roadmap for the US
9.2.1. Cell Processing
9.2.2. Cell Preservation, Distribution and Handling
9.2.3. Process Automation and Data Analytics
9.2.4. Process Monitoring and Quality Control
9.2.5. Standardization and Regulatory Support
9.2.6. Workforce Development
9.2.7. Supply Chain and Logistics
9.3. Roadmaps for Other Geographies
9.3.1. Europe
9.3.2. Asia Pacific

10. AUTOMATION TECHNOLOGIES FOR CELL THERAPY MANUFACTURING

10.1. Chapter Overview
10.2. Automation of Cell Therapy Manufacturing Processes
10.2.1. Closed Systems
10.2.2. Single-use Systems
10.2.3. Modular Systems
10.3. Growth Drivers and Roadblocks

10.4. Case Studies
10.4.1. Roadmap to Develop an Automated Cell Manufacturing / Processing Device
10.4.2. Automating the Cell Therapy Manufacturing Process

10.5. GMP-in-a-Box
10.6. List of Automated and Closed Cell Therapy Processing Systems
10.7. Comparative Analysis of Manual and Automated Processes

11. COMPANY PROFILES: INDUSTRY PLAYERS

11.1. Chapter Overview
11.2. Service Providers in North America
11.2.1. AGC Biologics
11.2.1.1. Company Overview
11.2.1.2. Financial Information
11.2.1.3. Service Portfolio
11.2.1.4. Manufacturing Facilities and Capabilities
11.2.1.5. Recent Developments and Future Outlook

11.2.2. Charles River Laboratories
11.2.2.1. Company Overview
11.2.2.2. Financial Information
11.2.2.3. Service Portfolio
11.2.2.4. Manufacturing Facilities and Capabilities
11.2.2.5. Recent Developments and Future Outlook

11.2.3. FUJIFILM Cellular Dynamics
11.2.3.1. Company Overview
11.2.3.2. Service Portfolio
11.2.3.3. Manufacturing Facilities and Capabilities
11.2.3.4. Recent Developments and Future Outlook

11.2.4. KBI Biopharma
11.2.4.1. Company Overview
11.2.4.2. Financial Information
11.2.4.3. Service Portfolio
11.2.4.4. Manufacturing Facilities and Capabilities
11.2.4.5. Recent Developments and Future Outlook

11.2.5. Thermo Fisher Scientific
11.2.5.1. Company Overview
11.2.5.2. Financial Information
11.2.5.3. Service Portfolio
11.2.5.4. Manufacturing Facilities and Capabilities
11.2.5.5. Recent Developments and Future Outlook

11.2.6. WuXi Advanced Therapies
11.2.6.1. Company Overview
11.2.6.2. Service Portfolio
11.2.6.3. Manufacturing Facilities and Capabilities
11.2.6.4. Recent Developments and Future Outlook

11.3. Service Providers in Europe
11.3.1. BioNTech Innovative Manufacturing Services
11.3.1.1. Company Overview
11.3.1.2. Service Portfolio
11.3.1.3. Manufacturing Facilities and Capabilities
11.3.1.4. Recent Developments and Future Outlook

11.3.2. Cell and Gene Therapy Catapult
11.3.2.1. Company Overview
11.3.2.2. Service Portfolio
11.3.2.3. Manufacturing Facilities and Capabilities
11.3.2.4. Recent Developments and Future Outlook

11.3.3. Lonza
11.3.3.1. Company Overview
11.3.3.2. Financial Information
11.3.3.3. Service Portfolio
11.3.3.4. Manufacturing Facilities and Capabilities
11.3.3.5. Recent Developments and Future Outlook

11.3.4. RoslinCT
11.3.4.1. Company Overview
11.3.4.2. Service Portfolio
11.3.4.3. Manufacturing Facilities and Capabilities
11.3.4.4. Recent Developments and Future Outlook

11.4. Service Providers in Asia Pacific
11.4.1. Cell Therapies
11.4.1.1. Company Overview
11.4.1.2. Service Portfolio
11.4.1.3. Manufacturing Facilities and Capabilities
11.4.1.4. Recent Developments and Future Outlook

11.4.2. Minaris Regenerative Medicine
11.4.2.1. Company Overview
11.4.2.2. Service Portfolio
11.4.2.3. Manufacturing Facilities and Capabilities
11.4.2.4. Recent Developments and Future Outlook

11.4.3. MEDINET
11.4.3.1. Company Overview
11.4.3.2. Service Portfolio
11.4.3.3. Manufacturing Facilities and Capabilities
11.4.3.4. Recent Developments and Future Outlook

11.4.4. Nikon CeLL Innovation
11.4.4.1. Company Overview
11.4.4.2. Service Portfolio
11.4.4.3. Manufacturing Facilities and Capabilities
11.4.4.4. Recent Developments and Future Outlook

12. COMPANY PROFILES: NON-INDUSTRY PLAYERS

12.1. Chapter Overview
12.2. Center for Cell and Gene Therapy, Baylor College of Medicine
12.2.1. Overview
12.2.2. Service Portfolio
12.2.3. Manufacturing Facilities and Capabilities
12.3. Centre for Cell Manufacturing Ireland, National University of Ireland
12.3.1. Overview
12.3.2. Service Portfolio
12.3.3. Manufacturing Facilities and Capabilities

12.4. Clinical Cell and Vaccine Production Facility, University of Pennsylvania
12.4.1. Overview
12.4.2. Service Portfolio
12.4.3. Manufacturing Facilities and Capabilities

12.5. Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
12.5.1. Overview
12.5.2. Service Portfolio
12.5.3. Manufacturing Facilities and Capabilities

12.6. Laboratory for Cell and Gene Medicine, Stanford University
12.6.1. Overview
12.6.2. Service Portfolio
12.6.3. Manufacturing Facilities and Capabilities

12.7. Molecular and Cellular Therapeutics, University of Minnesota
12.7.1. Overview
12.7.2. Service Portfolio
12.7.3. Manufacturing Facilities and Capabilities

12.8. Newcastle Cellular Therapies Facility, Newcastle University
12.8.1. Overview
12.8.2. Service Portfolio
12.8.3. Manufacturing Facilities and Capabilities

12.9. Rayne Cell Therapy Suite, King’s College London
12.9.1. Overview
12.9.2. Service Portfolio
12.9.3. Manufacturing Facilities and Capabilities

12.10. Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
12.10.1. Overview
12.10.2. Service Portfolio
12.10.3. Manufacturing Facilities and Capabilities

12.11. Sydney Cell and Gene Therapy
12.11.1. Overview
12.11.2. Service Portfolio
12.11.3. Manufacturing Facilities and Capabilities

13. NON-PROFIT ORGANIZATIONS IN CELL THERAPY MANUFACTURING

13.1. Chapter Overview
13.2. Cell Therapy Manufacturing: Non-Profit Organizations
13.2.1. CellCAN
13.2.2. Cell Therapy Manufacturing Cooperative Research Center
13.2.3. National Cell Manufacturing Consortium (NCMC)
13.2.4. California Institute of Regenerative Medicine (CIRM)
13.3. Cell Therapy Manufacturing: International Societies

14. CLINICAL TRIAL ANALYSIS

14.1. Chapter Overview
14.2. Scope and Methodology
14.3. Cell Therapies: Clinical Trial Analysis
14.3.1. Analysis by Trial Registration Year
14.3.2. Analysis by Tria Registration Year and Enrolled Patient Population
14.3.3. Analysis by Trial Status
14.3.4. Analysis by Trial Registration Year and Trial Status
14.3.5. Analysis by Trial Phase
14.3.6. Analysis of Number of Clinical Trials and Enrolled Patient Population by Trial Phase
14.3.7. Analysis by Type of Sponsor / Collaborator
14.3.8. Analysis by Patient Segment
14.3.9. Analysis by Study Design
14.3.10. Most Active Players: Analysis by Number of Registered Trials
14.3.11. Analysis by Number of Trials and Geography
14.3.12. Analysis by Number of Trials, Trial Status and Geography
14.3.13. Analysis by Enrolled Patient Population, Trial Status and Geography

15. PARTNERSHIPS AND COLLABORATIONS

15.1. Chapter Overview
15.2. Partnership Models
15.3. Cell Therapy Manufacturing: List of Partnerships
15.3.1. Analysis by Year of Partnership
15.3.2. Analysis by Type of Partnership
15.3.3. Analysis by Year and Type of Partnership

15.4. Analysis by Type of Cells
15.5. Analysis by Scale of Operation

15.6. Analysis by Region
15.6.1. Country-wise Distribution
15.6.2. Continent-wise Distribution

15.7. Most Active Players: Analysis by Number of Partnerships

15.8. Cell Therapy Manufacturing: List of Mergers and Acquisitions
15.8.1. Analysis by Year of Agreement
15.8.2. Analysis by Type of Agreement
15.8.3. Analysis by Year of Acquisition and Type of Cells

15.8.4. Analysis by Region
15.8.4.1. Country-wise Distribution
15.8.4.2. Continent-wise Distribution
15.8.4.3. Intercontinental and Intracontinental Deals

15.8.5. Ownership Change Matrix

16. RECENT EXPANSIONS

16.1. Chapter Overview
16.2. Cell Therapy Manufacturing: List of Expansions
16.2.1. Analysis by Year of Expansion
16.2.2. Analysis by Type of Expansion
16.2.3. Analysis by Type of Cell Manufactured
16.2.4. Analysis by Scale of Operation
16.2.5. Analysis by Location of Manufacturing Facility
16.2.6. Analysis by Type of Expansion and Location of Manufacturing Facility
16.2.7. Most Active Players: Analysis by Number of Expansions
16.2.8. Most Active Players: Analysis by Area of Expansion
16.2.9. Analysis by Year and Location of Manufacturing Facility

17. BIG PHARMA INITIATIVES

17.1. Chapter Overview
17.2. List of Cell Therapy Manufacturing Focused Initiatives of Big Pharma Players
17.2.1. Analysis by Number of Initiatives
17.2.2. Analysis by Year of Initiative
17.2.3. Analysis by Type of Initiative
17.2.3.1. Analysis by Type of Partnership
17.2.3.2. Analysis by Type of Expansion

17.2.4. Analysis by Types of Cells Manufactured
17.2.5. Analysis by Scale of Operation
17.2.6. Analysis of Big Pharma Players by Year of Initiative
17.2.7. Analysis by Year and Type of Initiative
17.2.8. Analysis of Big Pharma Players by Types of Cells Manufactured
17.2.9. Analysis of Big Pharma Players by Scale of Operation

17.3. Competitive Benchmarking of Big Pharmaceutical Players
17.3.1. Harvey Ball Analysis: Big Pharma Initiatives Summary
17.3.2. Spider Web Analysis: Big Pharmaceutical Players

18. CAPACITY ANALYSIS

18.1. Chapter Overview
18.2. Industry Players: Key Assumptions and Methodology
18.2.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
18.2.1.1. Analysis by Company Size
18.2.1.2. Analysis by Scale of Operation
18.2.1.3. Analysis by Location of Manufacturing Facility
18.2.1.4. Analysis by Company Size and Location of Manufacturing Facility
18.2.1.5. Analysis by Scale of Operation and Location of Manufacturing Facility
18.2.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
18.2.2.1. Analysis by Company Size
18.2.2.2. Analysis by Scale of Operation
18.2.2.3. Analysis by Location of Manufacturing Facility
18.2.2.4. Analysis by Company Size and Location of Manufacturing Facility
18.2.2.5. Analysis by Scale of Operation and Location of Manufacturing Facility

18.3. Non- Industry Players: Key Assumptions and Methodology
18.3.1. Cell Therapy Manufacturing: Installed Global Capacity (Number of Cleanrooms)
18.3.1.1. Analysis by Scale of Operation
18.3.1.2. Analysis by Location of Manufacturing Facility

18.3.2. Cell Therapy Manufacturing: Installed Global Capacity (Cleanroom Area)
18.3.2.1. Analysis by Scale of Operation
18.3.2.2. Analysis by Location of Manufacturing Facility

18.4. Concluding Remarks

19. DEMAND ANALYSIS

19.1. Chapter Overview
19.2. Scope and Methodology
19.3 Global Demand for Cell Therapy Manufacturing
19.4. Global Clinical Demand for Cell Therapy Manufacturing
19.4.1. Analysis by Type of Cell Therapy
19.4.2. Analysis by Geography

19.5. Global Commercial Demand for Cell Therapy Manufacturing
19.5.1. Commercial Demand: Analysis by Type of Cell Therapy
19.5.2. Commercial Demand: Analysis by Geography

20. COST PRICE ANALYSIS

20.1. Chapter Overview
20.2. Factors Contributing to the High Price of Cell Therapies
20.3. Pricing Models for Cell Therapies
20.3.1. Based on Associated Costs for T-Cell Therapies
20.3.2. Based on Associated Costs for Stem Cell Therapies
20.3.3. Based on Availability of Competing Products
20.3.4. Based on Target Patient Segment
20.3.5. Based on the Opinions of Industry Experts

20.4. Cell Therapy Cost Optimization
20.4.1. Role of Cost of Goods Sold
20.4.2. Role of Automation

20.5. Role of Cell Therapy Contract Manufacturing Organizations

20.6. Reimbursement-related Considerations for Cell Therapies
20.6.1. Case Study: The National Institute for Health and Care Excellence’s (NICE) Appraisal of CAR-T Therapies

21. MAKE VERSUS BUY DECISION MAKING FRAMEWORK

21.1. Chapter Overview
21.2. Assumptions and Key Parameters
21.3. Cell Therapy Manufacturing: Make versus Buy Decision Making
21.3.1. Scenario 1
21.3.2. Scenario 2
21.3.3. Scenario 3
21.3.4. Scenario 4

21.4. Concluding Remarks

22. TOTAL COST OF OWNERSHIP FOR CELL THERAPY MANUFACTURING ORGANIZATIONS

22.1. Chapter Overview
22.2. Key Parameters
22.3. Assumptions and Methodology
22.4. Sample Dataset for the Estimation of Total Cost of Ownership
22.5. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20
22.6. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX and OPEX, Y0 and Y20
22.6.1. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by CAPEX, Y0
22.6.2. Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Analysis by OPEX, Y1-Y20

23. GLOBAL CELL THERAPY MANUFACTURING MARKET

23.1. Chapter Overview
23.2. Scope of the Forecast
23.3. Input Data and Key Assumptions
23.4. Forecast Methodology
23.5. Global Cell Therapy Manufacturing Market, Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
23.5.1. Scenario Analysis
23.5.1.1. Conservative Scenario
23.5.1.2. Optimistic Scenario

23.6. Key Market Segmentations

24. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF CELL THERAPY

24.1. Chapter Overview
24.2. Key Assumptions and Methodology
24.3. Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022, 2024 and 2035
24.3.1. T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
24.3.1.1. CAR-T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
24.3.1.2. TCR Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
24.3.1.3. TIL Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)

24.3.2. Stem Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
24.3.3. Dendritic Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
24.3.4. NK Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)

24.4. Data Triangulation and Validation

25. CELL THERAPY MANUFACTURING MARKET, BY SOURCE OF CELLS

25.1. Chapter Overview
25.2. Key Assumptions and Methodology
25.3. Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022, 2024 and 2035
25.3.1. Autologous Source of Cells: Historical Trends (2022-2035) and Forecasted Estimates (2024-2035)
25.3.2. Allogeneic Source of Cells: Historical Trends (2022-2035) and Forecasted Estimates (2024-2035)
25.3.3. Unspecified Source of Cells: Historical Trends (2022-2035) and Forecasted Estimates (2024-2035)

25.4. Data Triangulation and Validation

26. CELL THERAPY MANUFACTURING MARKET, BY SCALE OF OPERATION

26.1. Chapter Overview
26.2. Key Assumptions and Methodology
26.3. Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022, 2024 And 2035
26.3.1. Clinical Scale: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035

26.4. Clinical Cell Therapy Manufacturing Market, by Type of Therapy
26.4.1. Clinical Scale Manufacturing Market for T Cell Therapies, 2022-2035
26.4.1.1. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035
26.4.1.2. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035
26.4.1.3. Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035

26.4.2. Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035
26.4.2.1. Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2022-2035
26.4.2.2. Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Geography, 2022-2035

26.4.3. Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
26.4.3.1. Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035
26.4.3.2. Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035

26.4.4. Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
26.4.4.1. Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035
26.4.4.2. Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, 2022-2035

26.4.5. Commercial Scale: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)

26.5. Commercial Cell Therapy Manufacturing Market, by Type of Cell Therapy
26.5.1. Commercial Scale Manufacturing Market for T Cell Therapies, 2022-2035
26.5.1.1. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035
26.5.1.2. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035
26.5.1.3. Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035

26.5.2. Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035
26.5.2.1. Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035

26.5.3. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035
26.5.3.1. Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035
26.5.3.2. Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035: Distribution by Geography

26.6. Data Triangulation and Validation

27. CELL THERAPY MANUFACTURING MARKET, BY TYPE OF MANUFACTURER

27.1. Chapter Overview
27.2. Key Assumptions and Methodology
27.3. Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer, 2022, 2024 And 2035
27.3.1. In-House Manufacturers: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
27.3.2. Contract Manufacturing Organizations: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)

27.4. Data Triangulation and Validation

28. CELL THERAPY MANUFACTURING MARKET, BY GEOGRAPHY

28.1. Chapter Overview
28.2. Key Assumptions and Methodology
28.3. Cell Therapy Manufacturing Market: Distribution by Geography, 2022, 2024 And 2035
28.3.1. North America: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
28.3.2. Europe: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
28.3.3. Asia Pacific: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035)
28.3.4. Rest of the World: Historical Trends (2022-2023) And Forecasted Estimates (2024-2035)

28.4. Data Triangulation and Validation

29. SWOT ANALYSIS

29.1. Chapter Overview
29.2. Strengths
29.3. Weaknesses
29.4. Opportunities
29.5. Threats
29.6. Comparison of SWOT Factors

30. SURVEY ANALYSIS

30.1. Chapter Overview
30.2. Analysis by Designation of Respondents
30.3. Analysis by Type of Cell Therapy
30.4. Analysis by Scale of Operation
30.5. Analysis by Source of Cells
30.6. Analysis by Type of Cell Culture System Used
30.7. Analysis by Availability of Fill / Finish Services

31. CONCLUDING REMARKS

32. EXECUTIVE INSIGHTS

32.1. Chapter Overview
32.2. Marketing Manager, Cell Therapy, Mid-sized Company in Australia
32.3. Director, Organization in UK
32.4. Marketing Director, Small Company in Belgium
32.5. Management Board Vice-President, Large Company in Poland
32.6. Senior Director of Sales Advanced Therapies; Vice President of Marketing, Small Company in US
32.7. Business Administration Department Manager, Mid-sized Company in Japan
32.8. Chief Business Officer, Small Company in Netherlands
32.9. Director of Finance and Facility Operations, Organization in US
32.10. Senior Director, Very Large Company in Japan
32.11. Chief Executive Officer, Mid-sized Company in UK
32.12. Former Chief Technical Officer, Cell and Gene Therapy, Large Company in US
32.13. Former Chief Executive Officer, Small Company in Netherlands
32.14. Former General Manager, Small Company in France
32.15. Chief Executive Officer, Large Company in China
32.16. Executive Vice President Research and Development, Small Company in Israel
32.17. Former Business Development Manager, Mid-sized Company in UK
32.18. Professor and American Red Cross Chair in Transfusion Medicine, Organization in US
32.19. Former Co-Founder and Chief Executive Officer, Small Company in Singapore
32.20. Former Manager, Business Development and Operations-cGMP Manufacturing Unit, Mid-sized Company in Canada
32.21. Manager of Business Development, Small Company in US
32.22. Former Department Leader, Cell Therapy Innovation and Development, Mid-sized Company in France
32.23. Former Chief Executive Officer, Mid-sized Company in Australia
32.24. Chief Executive Officer, Small Company in Netherlands

APPENDIX 1: TABULATED DATAAPPENDIX 2: LIST OF COMPANIES AND ORGANIZATIONS

LIST OF FIGURES

Figure 2.1 Research Methodology: Project Methodology
Figure 2.2 Research Methodology: Forecast Methodology
Figure 2.3 Research Methodology: Robust Quality Control
Figure 2.4 Research Methodology: Key Market Segmentations
Figure 3.1 Economic and Other Project Specific Consideration: Lesson Learnt from Past Recessions
Figure 4.1 Executive Summary: Market Landscape
Figure 4.2 Executive Summary: Clinical Trial Analysis
Figure 4.3 Executive Summary: Partnerships and Collaborations
Figure 4.4 Executive Summary: Mergers and Acquisitions
Figure 4.5 Executive Summary: Recent Expansions
Figure 4.6 Executive Summary: Big Pharma Initiatives
Figure 4.7 Executive Summary: Capacity Analysis
Figure 4.8 Executive Summary: Demand Analysis
Figure 4.9 Executive Summary: Market Sizing and Opportunity Analysis
Figure 5.1 Classification of Advanced Therapy Medicinal Products (ATMPs)
Figure 5.2 Decentralized Manufacturing: Process Model
Figure 5.3 Cell Therapy Manufacturing: Type of Manufacturers
Figure 5.4 Cell Therapies: Challenges and Drivers
Figure 5.5 Cell Therapies: Potency as a Critical Quality Attribute
Figure 5.6 Cell Therapy Manufacturing: Supply Chain Model
Figure 6.1 Industry Players: Distribution by Year of Establishment
Figure 6.2 Industry Players: Distribution by Company Size
Figure 6.3 Industry Players: Distribution by Location of Headquarters (Region)
Figure 6.4 Industry Players: Distribution by Location of Headquarters (Country)
Figure 6.5 Industry Players: Distribution by Company Size and Location of Headquarters (Region)
Figure 6.6 Industry Players: Distribution by Location of Manufacturing Facilities (Region)
Figure 6.7 Industry Players: Distribution by Location of Manufacturing Facilities (Country)
Figure 6.8 Industry Players: Distribution by Type of Manufacturer
Figure 6.9 Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Figure 6.10 Industry Players: Distribution by Type of Cell Manufactured
Figure 6.11 Industry Players: Distribution by Type of Immune Cell Manufactured
Figure 6.12 Industry Players: Distribution by Type of Stem Cell Manufactured
Figure 6.13 Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 6.14 Industry Players: Distribution by Source of Cells
Figure 6.15 Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Figure 6.16 Industry Players: Distribution by Scale of Operation
Figure 6.17 Industry Players: Distribution by Additional Services Offered
Figure 6.18 Industry Players: Distribution by Company Size and Additional Services Offered
Figure 7.1 Non-Industry Players: Distribution by Year of Establishment
Figure 7.2 Non-Industry Players: Distribution by Location of Headquarters (Region)
Figure 7.3 Non-Industry Players: Distribution by Location of Headquarters (Country)
Figure 7.4 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Figure 7.5 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Figure 7.6 Non-Industry Players: Distribution by Type of Manufacturer
Figure 7.7 Non-Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Figure 7.8 Non-Industry Players: Distribution by Type of Cell Manufactured
Figure 7.9 Non-Industry Players: Distribution by Type of Immune Cell Manufactured
Figure 7.10 Non-Industry Players: Distribution by Type of Stem Cell Manufactured
Figure 7.11 Non-Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Figure 7.12 Non-Industry Players: Distribution by Source of Cells
Figure 7.13 Non-Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Figure 7.14 Non-Industry Players: Distribution by Scale of Operation
Figure 7.15 Non-Industry Players: Distribution by Additional Services Offered
Figure 8.1 Industry Players: Distribution of Manufacturing Facilities by Regulatory Authorities
Figure 8.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Figure 10.1 Key Considerations for Automating Cell Therapy Manufacturing Process
Figure 10.2 Requirements to Implement Closed Systems in Cell Therapy Manufacturing Processes
Figure 10.3 Functions of Automated and Closed Systems at Each Step of the Cell Therapy Manufacturing Process
Figure 10.4 Advantages and Disadvantages of Single-Use System
Figure 10.5 Growth Drivers and Roadblocks to the Automated and Closed Systems
Figure 10.6 Cell Therapy Manufacturing: Roadmap for Developing an Automated Device
Figure 10.7 Cell Therapy Manufacturing: Comparison Between Manual and Automated Processes
Figure 10.8 Cell Therapy Manufacturing: Comparative Analysis of Manual and Automated Processes Based on Affiliated Costs
Figure 11.1 AGC Biologics: Annual Revenues, FY 2020- Q1 FY 2024 (YEN Billion)
Figure 11.2 Charles River Laboratories: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Figure 11.3 Thermo Fisher Scientific: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Figure 11.4 Lonza: Annual Revenues, FY 2019-FY 2023 (CHF Million)
Figure 12.1 Center for Cell and Gene Therapy: Service Portfolio
Figure 12.2 Center for Cell Manufacturing Ireland: Service Portfolio
Figure 12.3 Clinical Cell and Vaccine Production Facility: Service Portfolio
Figure 12.4 Guy’s and St Thomas’ GMP Facility: Service Portfolio
Figure 12.5 Laboratory for Cell and Gene Medicine: Service Portfolio
Figure 12.6 Molecular and Cellular Therapeutics: Service Portfolio
Figure 12.7 Newcastle Cellular Therapies Facility: Service Portfolio
Figure 12.8 Rayne Cell Therapy Suite, King’s College London: Service Portfolio
Figure 12.9 Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Center for Regenerative Medicine: Service Portfolio
Figure 12.10 Sydney Cell and Gene Therapy: Service Portfolio
Figure 14.1 Clinical Trial Analysis: Scope and Methodology
Figure 14.2 Clinical Trial Analysis: Distribution by Trial Registration Year, 2018-2024
Figure 14.3 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2018-2024
Figure 14.4 Clinical Trial Analysis: Distribution by Trial Status
Figure 14.5 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Figure 14.6 Clinical Trial Analysis: Distribution by Trial Phase
Figure 14.7 Clinical Trial Analysis: Distribution of Trial Phase by Number of Trials and Enrolled Patient Population
Figure 14.8 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Figure 14.9 Clinical Trial Analysis: Distribution by Patient Segment
Figure 14.10 Clinical Trial Analysis: Distribution by Study Design
Figure 14.11 Most Active Industry Players: Distribution by Number of Registered Trials
Figure 14.12 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Figure 14.13 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Figure 14.14 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Figure 14.15 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
Figure 15.1 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Figure 15.2 Partnerships and Collaborations: Distribution by Type of Partnership
Figure 15.3 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Figure 15.4 Partnerships and Collaborations: Distribution by Type of Cells
Figure 15.5 Heat Map: Distribution by Year and Type of Cells
Figure 15.6 Partnerships and Collaborations: Distribution by Type of T-Cells
Figure 15.7 Partnerships and Collaborations: Distribution by Type of Stem Cells
Figure 15.8 Partnerships and Collaborations: Distribution by Scale of Operation
Figure 15.9 Partnerships and Collaborations: Distribution by Type of Cells and Scale of Operation
Figure 15.10 Partnerships and Collaborations: Country-wise Distribution
Figure 15.11 Partnerships and Collaborations: Continent-wise Distribution
Figure 15.12 Most Active Players: Distribution by Number of Partnerships
Figure 15.13 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022 (till June)
Figure 15.14 Mergers and Acquisitions: Distribution by Type of Agreement
Figure 15.15 Mergers and Acquisitions: Year-wise Distribution by Type of Cells
Figure 15.16 Mergers and Acquisitions: Country-wise Distribution
Figure 15.17 Mergers and Acquisitions: Continent-wise Distribution
Figure 15.18 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Figure 15.19 Mergers and Acquisitions: Ownership Change Matrix
Figure 16.1 Recent Expansions: Cumulative Year-wise Trend, 2017-2024
Figure 16.2 Recent Expansions: Distribution by Type of Expansion
Figure 16.3 Recent Expansions: Distribution by Year and Type of Expansion
Figure 16.4 Recent Expansions: Distribution by Type of Cells Manufactured
Figure 16.5 Recent Expansions: Distribution by Type of Expansion and Type of Cells Manufactured
Figure 16.6 Recent Expansions: Distribution by Scale of Operation
Figure 16.7 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Figure 16.8 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Figure 16.9 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Figure 16.10 Most Active Players: Distribution by Number of Expansions
Figure 16.11 Most Active Players: Distribution by Area of Expansion (in sq ft)
Figure 16.12 Recent Expansions: Distribution by Year and Location of Manufacturing Facility
Figure 17.1 Big Pharma Players: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Figure 17.2 Big Pharma Players: Distribution by Year of Initiative
Figure 17.3 Big Pharma Initiatives: Distribution by Type of Initiative
Figure 17.4 Big Pharma Players: Distribution by Type of Partnership
Figure 17.5 Big Pharma Players: Distribution by Type of Expansion
Figure 17.6 Big Pharma Players: Distribution by Type of Cells
Figure 17.7 Big Pharma Players: Distribution by Scale of Operation
Figure 17.8 Big Pharma Players: Distribution of Big Pharma Players by Year and Number of Initiatives
Figure 17.9 Big Pharma Players: Distribution by Year and Type of Initiative
Figure 17.10 Big Pharma Players: Distribution of Type of Cells Manufactured
Figure 17.11 Big Pharma Players: Distribution by Scale of Operation
Figure 17.12 Harvey Ball Analysis: Big Pharma Initiatives Summary
Figure 17.13 Spider Web Analysis: Big Pharmaceutical Players
Figure 18.1 Sample Dataset Capacity of Industry Players for Cell Therapy Manufacturing (Number of Cleanrooms): Distribution by Company Size and Range of Installed Capacity
Figure 18.2 Sample Dataset Capacity of Industry Players for Cell Therapy Manufacturing (Cleanroom Area, sq. ft.): Distribution by Company Size and Range of Installed Capacity
Figure 18.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Figure 18.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 18.5 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 18.6 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size and Location of Manufacturing Facility
Figure 18.7 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 18.8 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Figure 18.9 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (in terms of Cleanroom Area): Distribution by Scale of Operation
Figure 18.10 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 18.11 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Figure 18.12 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Figure 18.13 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Range of Installed Capacity
Figure 18.14 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Figure 18.15 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Figure 18.16 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Range of Installed Capacity
Figure 18.17 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Figure 18.18 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Figure 19.1 Global Demand for Cell Therapies, 2024-2035 (in terms of Number of Patients)
Figure 19.2 Global Demand for Cell Therapies, 2024-2035 (in terms of Billion Cells)
Figure 19.3 Global Clinical Demand for Cell Therapies, 2024-2035 (in terms of Number of Patients)
Figure 19.4 Global Clinical Demand for Cell Therapies: Distribution by Type of Cell Therapy, 2024-2035 (in terms of Number of Patients)
Figure 19.5 Global Clinical Demand for Cell Therapies: Distribution by Geography, 2024-2035 (in terms of Number of Patients)
Figure 19.6 Global Commercial Demand for Cell Therapies, 2024-2035 (in terms of Number of Patients)
Figure 19.7 Global Commercial Demand for Cell Therapies: Distribution by Type of Cell Therapy, 2024-2035 (in terms of Number of Patients)
Figure 19.8 Global Commercial Demand for Cell Therapies: Distribution by Geography, 2024-2035 (in terms of Number of Patients)
Figure 20.1 Targeted Therapies: Pricing Model Based on Patient Segment
Figure 21.1 Make versus Buy Decision Making Framework
Figure 21.2 Make versus Buy Decision Making: Possible Scenario Descriptions
Figure 22.1 Total Cost of Ownership: Capital Expenditures (CAPEX)
Figure 22.2 Total Cost of Ownership: Operational Expenditures (OPEX)
Figure 22.3 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Figure 22.4 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Figure 22.5 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution by CAPEX (USD Million)
Figure 22.6 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Figure 23.1 Global Cell Therapy Manufacturing Market, Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Figure 23.2 Global Cell Therapy Manufacturing Market, Forecasted Estimates (2024-2035): Conservative Scenario (USD Billion)
Figure 23.3 Global Cell Therapy Manufacturing Market, Forecasted Estimates (2024-2035): Optimistic Scenario (USD Billion)
Figure 24.1 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022, 2024 and 2035
Figure 24.2 Cell Therapy Manufacturing Market for T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.3 T Cell Therapy Manufacturing Market for CAR-T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.4 T Cell Therapy Manufacturing Market for TCR Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.5 T Cell Therapy Manufacturing Market for TIL Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.6 Cell Therapy Manufacturing Market for Stem Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.7 Cell Therapy Manufacturing Market for Dendritic Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 24.8 Cell Therapy Manufacturing Market for NK Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 25.1 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022, 2024 and 2035
Figure 25.2 Cell Therapy Manufacturing Market for Autologous Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 25.3 Cell Therapy Manufacturing Market for Allogeneic Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 25.4 Cell Therapy Manufacturing Market for Unspecified Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 26.1 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022, 2024 and 2035
Figure 26.2 Cell Therapy Manufacturing Market for Clinical Scale: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 26.3 Clinical Scale Manufacturing Market for T Cell Therapies, 2022-2035 (USD Million)
Figure 26.4 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 26.5 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.6 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.7 Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Figure 26.8 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.9 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.10 Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 26.11 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.12 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.13 Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Figure 26.14 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.15 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.16 Cell Therapy Manufacturing Market for Commercial Scale: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 26.17 Commercial Scale Manufacturing Market for T Cell Therapies, 2022-2035 (USD Million)
Figure 26.18 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Figure 26.19 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.20 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.21 Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Figure 26.22 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Figure 26.23 Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Figure 26.24 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Figure 26.25 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, 2022-2035 (USD Million
Figure 27.1 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer, 2022, 2024 and 2035
Figure 27.2 Cell Therapy Manufacturing Market for In-house Manufacturers: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 27.3 Cell Therapy Manufacturing Market for Contract Manufacturing Organizations: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 28.1 Cell Therapy Manufacturing Market: Distribution by Geography, 2022, 2024 and 2035
Figure 28.2 Cell Therapy Manufacturing Market in North America: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 28.3 Cell Therapy Manufacturing Market in Europe: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 28.4 Cell Therapy Manufacturing Market in Asia Pacific: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Figure 28.5 Cell Therapy Manufacturing Market in Rest of the World: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million
Figure 29.1 Cell Therapy Manufacturing: SWOT Analysis
Figure 29.2 Comparison of SWOT Factors: Harvey Ball Analysis
Figure 30.1 Survey Insights: Distribution of Respondents by Type of Organization
Figure 30.2 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Figure 30.3 Survey Insights: Distribution by Designation and Seniority of Respondents
Figure 30.4 Survey Insights: Distribution by Type of Cell Therapy
Figure 30.5 Survey Insights: Distribution by Scale of Operation
Figure 30.6 Survey Insights: Distribution by Source of Cells
Figure 30.7 Survey Insights: Distribution by Cell Culture System
Figure 30.8 Survey Insights: Distribution by Availability of Fill / Finish Services
Figure 31.1 Concluding Remarks: Market Landscape
Figure 31.2 Concluding Remarks: Partnerships and Collaborations
Figure 31.3 Concluding Remarks: Mergers and Acquisitions
Figure 31.4 Concluding Remarks: Recent Expansions
Figure 31.5 Concluding Remarks: Big Pharma Initiatives
Figure 31.6 Concluding Remarks: Capacity Analysis
Figure 31.7 Concluding Remarks: Demand Analysis
Figure 31.8 Concluding Remarks: Total Cost of Ownership
Figure 31.9 Concluding Remarks: Market Sizing and Opportunity Analysis (1/2)
Figure 31.10 Concluding Remarks: Market Sizing and Opportunity Analysis (2/2)

LIST OF TABLES

Table 5.2 Differences between Cell Therapy and Biotechnological Products
Table 5.3 Cell-based Therapies: Commercialized Products
Table 5.4 Assessments for Key Cell Therapy Manufacturing Steps
Table 5.5 Advantages and Disadvantages of Centralized and Decentralized Manufacturing Models
Table 6.1 Cell Therapy Manufacturing: List of Industry Players
Table 6.2 Industry Players: Information on Type of Manufacturer
Table 6.3 Industry Players: Information on Type of Cell Manufactured
Table 6.4 Industry Players: Information on Source of Cells and Type of Cells Culture System Used
Table 6.5 Industry Players: Information on Scale of Operation
Table 6.6 Industry Players: Information on Additional Services Offered
Table 7.1 Cell Therapy Manufacturing: List of Non-Industry Players
Table 7.2 Non-Industry Players: Information on Type of Cell Manufactured
Table 7.3 Non-Industry Players: Information on Source of Cells and Type of Cells Culture System Used
Table 7.4 Non-Industry Players: Information on Scale of Operation
Table 7.5 Non-Industry Players: Information on Additional Services Offered
Table 8.1 Cell Therapy Manufacturing (Industry Players): Regulatory Authorities
Table 8.2 Cell Therapy Manufacturing (Non-Industry Players): Regulatory Authorities
Table 8.3 Summary of Guidelines for Early-Stage Manufacturing of Cell Therapies
Table 9.1 Cell Therapy Manufacturing: Roadmap for the US
Table 9.2 Cell Processing: Challenges and Strategies
Table 9.3 Cell Preservation, Distribution and Handling: Challenges and Strategies
Table 9.4 Process Monitoring and Quality Control: Challenges and Strategies
Table 9.5 Standardization and Regulatory Support: Challenges and Strategies
Table 9.6 Workforce Development: Challenges and Strategies
Table 9.7 Supply Chain and Logistics: Challenges and Strategies
Table 9.8 Cell Therapy Manufacturing: Roadmap for the Asia Pacific Economic Cooperation (APEC)
Table 10.1 Cell Therapy Manufacturing: List of Automated and Closed Cell Therapy Processing Systems
Table 11.1 Cell Therapy Manufacturing Industry Players: List of Companies Profiled
Table 11.2 AGC Biologics: Company Snapshot
Table 11.3 AGC Biologics: Information on Manufacturing Facilities and Capabilities
Table 11.4 AGC Biologics: Recent Developments and Future Outlook
Table 11.5 Charles River Laboratories: Company Snapshot
Table 11.6 Charles River Laboratories: Information on Manufacturing Facilities and Capabilities
Table 11.7 Charles River Laboratories: Recent Developments and Future Outlook
Table 11.8 FUJIFILM Cellular Dynamics: Company Snapshot
Table 11.9 FUJIFILM Cellular Dynamics: Information on Manufacturing Facilities and Capabilities
Table 11.10 FUJIFILM Cellular Dynamics: Recent Developments and Future Outlook
Table 11.11 KBI Biopharma: Company Snapshot
Table 11.12 KBI Biopharma: Information on Manufacturing Facilities and Capabilities
Table 11.13 KBI Biopharma: Recent Developments and Future Outlook
Table 11.14 Thermo Fisher Scientific: Company Snapshot
Table 11.15 Thermo Fisher Scientific: Information on Manufacturing Facilities and Capabilities
Table 11.16 Thermo Fisher Scientific: Recent Developments and Future Outlook
Table 11.17 Wuxi Advanced Therapies: Company Snapshot
Table 11.18 Wuxi Advanced Therapies: Information on Manufacturing Facilities and Capabilities
Table 11.19 Wuxi Advanced Therapies: Recent Developments and Future Outlook
Table 11.20 BioNTech: Company Snapshot
Table 11.21 BioNTech: Information on Manufacturing Facilities and Capabilities
Table 11.22 BioNTech: Recent Developments and Future Outlook
Table 11.23 Cell and Gene Therapy Catapult: Company Snapshot
Table 11.24 Cell and Gene Therapy Catapult: Information on Manufacturing Facilities and Capabilities
Table 11.25 Cell and Gene Therapy Catapult: Recent Developments and Future Outlook
Table 11.26 Lonza: Company Snapshot
Table 11.27 Lonza: Information on Manufacturing Facilities and Capabilities
Table 11.28 Lonza: Recent Developments and Future Outlook
Table 11.29 RoslinCT: Company Snapshot
Table 11.30 RoslinCT: Information on Manufacturing Facilities and Capabilities
Table 11.31 RoslinCT: Recent Developments and Future Outlook
Table 11.32 Cell Therapies: Company Snapshot
Table 11.33 Cell Therapies: Information on Manufacturing Facilities and Capabilities
Table 11.34 Cell Therapies: Recent Developments and Future Outlook
Table 11.35 Minaris Regenerative Medicine: Company Snapshot
Table 11.36 Minaris Regenerative Medicine: Information on Manufacturing Facilities and Capabilities
Table 11.37 Minaris Regenerative Medicine: Recent Developments and Future Outlook
Table 11.38 MEDINET: Company Snapshot
Table 11.39 MEDINET: Information on Manufacturing Facilities and Capabilities
Table 11.40 Nikon CeLL Innovation: Company Snapshot
Table 11.41 Nikon CeLL Innovation: Information on Manufacturing Facilities and Capabilities
Table 12.1 Cell Therapy Manufacturing (Non-Industry Players): List of Organizations Profiled
Table 12.2 Center for Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 12.3 Center for Cell Manufacturing Ireland: Overview of Manufacturing Facilities and Capabilities
Table 12.4 Clinical Cell and Vaccine Production Facility: Overview of Manufacturing Facilities and Capabilities
Table 12.5 Guy’s and St. Thomas GMP Facility: Overview of Manufacturing Facilities and Capabilities
Table 12.6 Laboratory of Cell and Gene Medicine: Overview of Manufacturing Facilities and Capabilities
Table 12.7 Molecular and Cellular Therapeutics: Overview of Manufacturing Facilities and Capabilities
Table 12.8 Newcastle Advanced Therapies: Overview of Manufacturing Facilities and Capabilities
Table 12.9 Rayne Cell Therapy Suite: Overview of Manufacturing Facilities and Capabilities
Table 12.10 Scottish National Blood Transfusion Services: Overview of Manufacturing Services and Capabilities
Table 12.11 Sydney Cell and Gene Therapy: Overview of Manufacturing Facilities and Capabilities
Table 13.1 Cell Therapy Manufacturing: List of Non-Profit Organizations
Table 13.2 CellCAN: Overview
Table 13.3 Cell Therapy Manufacturing Cooperative Research Center: Overview
Table 13.4 National Cell Manufacturing Consortium: Overview
Table 13.5 California’s Institute of Regenerative Medicine: Overview
Table 15.1 Cell Therapy Manufacturing: List of Partnerships and Collaborations
Table 15.2 Partnerships and Collaborations: Information on Type of Cells
Table 15.3 Partnerships and Collaborations: Information on Types of T Cells and Stem Cells
Table 15.4 Partnerships and Collaborations: Information on Scale of Operation
Table 15.5 Cell Therapy Manufacturing: List of Mergers and Acquisitions
Table 16.1 Cell Therapy Manufacturing: List of Expansions
Table 16.2 Recent Expansions: Information on Type of Cell Manufactured
Table 16.3 Recent Expansions: Information on Scale of Operation
Table 17.1 Big Pharma Players: List of Cell Therapy Manufacturing Focused Initiatives, 2017-2022
Table 17.2 Big Pharma Players: Information on Type of Cells Manufactured
Table 17.3 Big Pharma Players: Information on Scale of Operation
Table 18.1 Average Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Sample Data Set for Industry Players
Table 18.2 Average Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Sample Data Set for Industry Players
Table 18.3 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Table 18.4 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Table 18.5 Median Installed Cell Therapy Manufacturing Capacity (Number of Cleanrooms): Data Set for Non-Industry Players
Table 18.6 Median Installed Cell Therapy Manufacturing Capacity (Cleanroom Area): Dat Set for Non-Industry Players
Table 20.1 Costs Associated with Manufacturing Stem Cell Therapies
Table 20.2 Pricing Model: Price of Marketed Drugs (Antibody Drug Conjugates and Monoclonal Antibodies)
Table 20.3 T-Cell Immunotherapies: Expert Opinions on Pricing
Table 20.4 CAR-T Cell Therapies: Reimbursement Landscape
Table 22.1 Total Cost of Ownership: Sample Dataset
Table 23.1 Active Clinical Studies for Cell Therapies
Table 23.2 Active Clinical Studies for Cell Therapies: Distribution by Patients Enrolled
Table 30.1 Survey Insights: Overview of Respondents
Table 30.2 Survey Insights: Designations and Seniority Levels
Table 30.3 Survey Insights: Type of Cell Therapy
Table 30.4 Survey Insights: Scale of Operation
Table 30.5 Survey Insights: Source of Cells
Table 30.6 Survey Insights: Cell Culture System
Table 30.7 Survey Insights: Availability of Fill / Finish Services
Table 33.1 Industry Players: Distribution by Year of Establishment
Table 33.2 Industry Players: Distribution by Company Size
Table 33.3 Industry Players: Distribution by Location of Headquarters (Region)
Table 33.4 Industry Players: Distribution by Location of Headquarters (Country)
Table 33.5 Industry Players: Distribution by Company Size and Location of Headquarters
Table 33.6 Industry Players: Distribution by Location of Manufacturing Facilities (Region)
Table 33.7 Industry Players: Distribution by Location of Manufacturing Facilities (Country)
Table 33.8 Industry Players: Distribution by Type of Manufacturer
Table 33.9 Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Table 33.10 Industry Players: Distribution by Type of Cells Manufactured
Table 33.11 Industry Players: Distribution by Type of Immune Cell Manufactured
Table 33.12 Industry Players: Distribution by Type of Stem Cell Manufactured
Table 33.13 Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Table 33.14 Industry Players: Distribution by Source of Cells
Table 33.15 Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Table 33.16 Industry Players: Distribution by Scale of Operation
Table 33.17 Industry Players: Distribution by Additional Services Offered
Table 33.18 Industry Players: Distribution by Company Size and Additional Services Offered
Table 33.19 Non-Industry Players: Distribution by Year of Establishment
Table 33.20 Non-Industry Players: Distribution by Location of Headquarters (Region)
Table 33.21 Non-Industry Players: Distribution by Location of Headquarters (Country)
Table 33.22 Non-Industry Players: Distribution by Location of Manufacturing Facility (Region)
Table 33.23 Non-Industry Players: Distribution by Location of Manufacturing Facility (Country)
Table 33.24 Non-Industry Players: Distribution by Type of Manufacturer
Table 33.25 Non-Industry Players: Distribution by Location of Headquarters and Type of Manufacturer
Table 33.26 Non-Industry Players: Distribution by Type of Cell Manufactured
Table 33.27 Non-Industry Players: Distribution by Type of Immune Cell Manufactured
Table 33.28 Non-Industry Players: Distribution by Type of Stem Cell Manufactured
Table 33.29 Non-Industry Players: Distribution by Location of Headquarters and Type of Cell Manufactured
Table 33.30 Non-Industry Players: Distribution by Source of Cells
Table 33.31 Non-Industry Players: Distribution by Type of Cell Manufactured and Source of Cells
Table 33.32 Non-Industry Players: Distribution by Scale of Operation
Table 33.33 Non-Industry Players: Distribution by Additional Services Offered
Table 33.34 AGC Biologics: Annual Revenues, FY 2020- Q1 FY 2024 (Billion YEN)
Table 33.35 Charles River Laboratories: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Table 33.36 Thermo Fisher Scientific: Annual Revenues, FY 2020-Q1 FY 2024 (USD Billion)
Table 33.37 Lonza: Annual Revenues, FY 2019-FY 2023 (CHF Million)
Table 33.38 Clinical Trial Analysis: Distribution by Trial Registration Year, 2018-2024
Table 33.39 Clinical Trial Analysis: Distribution by Trial Registration Year and Enrolled Patient Population, 2018-2024
Table 33.40 Clinical Trial Analysis: Distribution by Trial Status
Table 33.41 Clinical Trial Analysis: Distribution by Trial Registration Year and Trial Status
Table 33.42 Clinical Trial Analysis: Distribution by Trial Phase
Table 33.43 Clinical Trial Analysis: Distribution of Trial Phase by Number of Trials and Enrolled Patient Population
Table 33.44 Clinical Trial Analysis: Distribution by Type of Sponsor / Collaborator
Table 33.45 Clinical Trial Analysis: Distribution by Patient Segment
Table 33.46 Clinical Trial Analysis: Distribution by Study Design
Table 33.47 Most Active Industry Players: Distribution by Number of Registered Trials
Table 33.48 Most Active Non-Industry Players: Distribution by Number of Registered Trials
Table 33.49 Clinical Trial Analysis: Distribution by Number of Trials and Geography
Table 33.50 Clinical Trial Analysis: Distribution by Number of Trials, Trial Status and Geography
Table 33.51 Clinical Trial Analysis: Distribution by Enrolled Patient Population, Trial Status and Geography
Table 33.52 Partnerships and Collaborations: Cumulative Year-wise Trend, 2016-2022
Table 33.53 Partnerships and Collaborations: Distribution by Type of Partnership
Table 33.54 Partnerships and Collaborations: Distribution by Year and Type of Partnership
Table 33.55 Partnerships and Collaborations: Distribution by Type of Cell
Table 33.56 Heat Map: Distribution by Year and Type of Cell
Table 33.57 Partnerships and Collaborations: Distribution by Type of T Cell
Table 33.58 Partnerships and Collaborations: Distribution by Type of Stem Cell
Table 33.59 Partnerships and Collaborations: Distribution by Scale of Operation
Table 33.60 Partnerships and Collaborations: Distribution by Type of Cell and Scale of Operation
Table 33.61 Partnerships and Collaborations: Country-wise Distribution
Table 33.62 Partnerships and Collaborations: Continent-wise Distribution
Table 33.63 Most Active Players: Distribution by Number of Partnerships and Collaborations
Table 33.64 Mergers and Acquisitions: Cumulative Year-wise Trend, 2016-2022
Table 33.65 Mergers and Acquisitions: Distribution by Type of Agreement
Table 33.66 Mergers and Acquisitions: Year-wise Distribution by Type of Cell
Table 33.67 Mergers and Acquisitions: Country-wise Distribution
Table 33.68 Mergers and Acquisitions: Continent-wise Distribution
Table 33.69 Mergers and Acquisitions: Intercontinental and Intracontinental Deals
Table 33.70 Mergers and Acquisitions: Ownership Change Matrix
Table 33.71 Recent Expansions: Cumulative Year-wise Trend, 2016-2022
Table 33.72 Recent Expansions: Distribution by Type of Expansion
Table 33.73 Recent Expansions: Distribution by Year and Type of Expansion
Table 33.74 Recent Expansions: Distribution by Type of Cell Manufactured
Table 33.75 Recent Expansions: Distribution by Type of Expansion and Type of Cell Manufactured
Table 33.76 Recent Expansions: Distribution by Scale of Operation
Table 33.77 Recent Expansions: Distribution by Location of Expanded Facility (Region)
Table 33.78 Recent Expansions: Distribution by Location of Expanded Facility (Country)
Table 33.79 Recent Expansions: Distribution by Type of Expansion and Location of Expanded Facility
Table 33.80 Most Active Players: Distribution by Number of Expansions
Table 33.81 Most Active Players: Distribution by Area of Expansion (in sq ft)
Table 33.82 Big Pharma Initiatives: Distribution by Number of Cell Therapy Manufacturing Focused Initiatives
Table 33.83 Big Pharma Initiatives: Cumulative Distribution by Year of Initiative
Table 33.84 Big Pharma Initiatives: Distribution by Type of Initiative
Table 33.85 Big Pharma Initiatives: Distribution by Type of Partnership
Table 33.86 Big Pharma Initiatives: Distribution by Type of Expansion
Table 33.87 Big Pharma Initiatives: Distribution by Type of Cells Manufactured
Table 33.88 Big Pharma Initiatives: Distribution by Scale of Operation
Table 33.89 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Number of Initiatives
Table 33.90 Big Pharma Initiatives: Distribution of Big Pharma Players by Year and Type of Initiative
Table 33.91 Big Pharma Players: Distribution by Scale of Operation and Big Pharma Players
Table 33.92 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Company Size
Table 33.93 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 33.94 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 33.95 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 33.96 Installed Global Capacity of Industry Players for Cell Therapy Manufacturing (Number of Cleanrooms): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 33.97 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size
Table 33.98 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 33.99 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 33.100 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Company Size and Location of Manufacturing Facility
Table 33.101 Installed Global Cell Therapy Manufacturing Capacity of Industry Players (Cleanroom Area): Distribution by Scale of Operation and Location of Manufacturing Facility
Table 33.102 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Scale of Operation
Table 33.103 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Number of Cleanrooms): Distribution by Location of Manufacturing Facility
Table 33.104 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Scale of Operation
Table 33.105 Installed Global Cell Therapy Manufacturing Capacity of Non-Industry Players (Cleanroom Area): Distribution by Location of Manufacturing Facility
Table 33.106 Global Demand for Cell Therapies, 2024-2035 (Number of Patients)
Table 33.107 Global Demand for Cell Therapies, 2024-2035 (Billion Cells)
Table 33.108 Global Clinical Demand for Cell Therapies, 2024-2035 (Number of Patients)
Table 33.109 Global Clinical Demand for Cell Therapies, 2024-2035: Distribution by Type of Cell Therapy (Number of Patients)
Table 33.110 Global Clinical Demand for Cell Therapies, 2024-2035: Distribution by Geography (Number of Patients)
Table 33.111 Global Commercial Demand for Cell Therapies, 2024-2035 (Number of Patients)
Table 33.112 Global Commercial Demand for Cell Therapies, 2024-2035: Distribution by Type of Cell Therapy (Number of Patients)
Table 33.113 Global Commercial Demand for Cell Therapies, 2024-2035: Distribution by Geography (Number of Patients)
Table 33.114 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0-Y20 (USD Million)
Table 33.115 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations: Distribution by CAPEX and OPEX, Y0 and Y20 (USD Million)
Table 33.116 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y0: Distribution of CAPEX (USD Million)
Table 33.117 Total Cost of Ownership for Mid-sized Cell Therapy Manufacturing Organizations, Y1-Y20: Distribution by OPEX (USD Million)
Table 33.118 Global Cell Therapy Manufacturing Market, Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Billion)
Table 33.119 Cell Therapy Manufacturing Market: Distribution by Type of Cell Therapy, 2022, 2024 and 2035 (USD Million)
Table 33.120 Cell Therapy Manufacturing Market for T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.121 T Cell Therapy Manufacturing Market for CAR-T Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.122 T Cell Therapy Manufacturing Market for TCR Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.123 T Cell Therapy Manufacturing Market for TIL Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.124 Cell Therapy Manufacturing Market for Stem Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.125 Cell Therapy Manufacturing Market for Dendritic Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.126 Cell Therapy Manufacturing Market for NK Cell Therapies: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.127 Cell Therapy Manufacturing Market: Distribution by Source of Cells, 2022, 2024, 2035 (USD Million)
Table 33.128 Cell Therapy Manufacturing Market for Autologous Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.129 Cell Therapy Manufacturing Market for Allogeneic Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.130 Cell Therapy Manufacturing Market for Unspecified Source of Cells: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.131 Cell Therapy Manufacturing Market: Distribution by Scale of Operation, 2022, 2024 and 2035
Table 33.132 Cell Therapy Manufacturing Market for Clinical Scale: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.133 Clinical Scale Manufacturing Market for T Cell Therapies, 2022-2035 (USD Million)
Table 33.134 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Table 33.135 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.136 Clinical Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.137 Clinical Scale Manufacturing Market for NK Cell Therapies, 2022-2035 (USD Million)
Table 33.138 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.139 Clinical Scale Manufacturing Market for NK Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.140 Clinical Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 33.141 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.142 Clinical Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.143 Clinical Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 33.144 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.145 Clinical Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.146 Cell Therapy Manufacturing Market for Commercial Scale: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.147 Commercial Scale Manufacturing Market for T Cell Therapies, 2022-2035 (USD Million)
Table 33.148 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Type of Therapy, 2022-2035 (USD Million)
Table 33.149 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.150 Commercial Scale Manufacturing Market for T Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.151 Commercial Scale Manufacturing Market for Dendritic Cell Therapies, 2022-2035 (USD Million)
Table 33. 152 Commercial Scale Manufacturing Market for Dendritic Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.153 Commercial Scale Manufacturing Market for Stem Cell Therapies, 2022-2035 (USD Million)
Table 33.154 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Source of Cells, 2022-2035 (USD Million)
Table 33.155 Commercial Scale Manufacturing Market for Stem Cell Therapies: Distribution by Geography, 2022-2035 (USD Million)
Table 33.156 Cell Therapy Manufacturing Market: Distribution by Type of Manufacturer, 2022, 2024 and 2035
Table 33.157 Cell Therapy Manufacturing Market for In-house Manufacturers: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.158 Cell Therapy Manufacturing Market for contract manufacturing organizations: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.159 Cell Therapy Manufacturing Market: Distribution by Geography, 2022, 2024 and 2035
Table 33.160 Cell Therapy Manufacturing Market in North America: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.161 Cell Therapy Manufacturing Market in Europe: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.162 Cell Therapy Manufacturing Market in Asia Pacific: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.163 Cell Therapy Manufacturing Market in Rest of the World: Historical Trends (2022-2023) and Forecasted Estimates (2024-2035) (USD Million)
Table 33.164 Survey Insights: Distribution of Respondents by Type of Organization
Table 33.165 Survey Insights: Distribution of Respondents by Location of Manufacturing Facility
Table 33.166 Survey Insights: Distribution by Designation and Seniority Level
Table 33.167 Survey Insights: Distribution by Type of Cell Therapy
Table 33.168 Survey Insights: Distribution by Scale of Operation
Table 33.169 Survey Insights: Distribution by Source of Cells
Table 33.170 Survey Insights: Distribution by Fill / Finish Services

Companies Mentioned (Partial List)

A selection of companies mentioned in this report includes, but is not limited to:

AGC Biologics
BioNTech Innovative Manufacturing Services
Cell and Gene Therapy Catapult
Cell Therapies
Center for Cell and Gene Therapy, Baylor College of Medicine
Centre for Cell Manufacturing Ireland, National University of Ireland
Charles River Laboratories
Clinical Cell and Vaccine Production Facility, University of Pennsylvania
FUJIFILM Cellular Dynamics
Guy’s and St. Thomas’ GMP Facility, Guy’s Hospital
KBI Biopharma
Laboratory for Cell and Gene Medicine, Stanford University
Lonza
MEDINET
Minaris Regenerative Medicine
Molecular and Cellular Therapeutics, University of Minnesota
Newcastle Cellular Therapies Facility, Newcastle University
Nikon CeLL Innovation
Rayne Cell Therapy Suite, King’s College London
RoslinCT
Scottish National Blood Transfusion Services Cellular Therapy Facility, Scottish Centre for Regenerative Medicine
Sydney Cell and Gene Therapy
Thermo Fisher Scientific
WuXi AppTec

Methodology

LOADING...

License	Format	Properties	Price
SINGLE USER LICENSE PDF	The product is a PDF.	This is a single user license, allowing one user access to the product.	€4762EUR$4,799USD£3,951GBP
SITE LICENSE PDF	The product is a PDF.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€6945EUR$6,999USD£5,762GBP
ENTERPRISE LICENSE PDF	The product is a PDF.	This is an enterprise license, allowing all employees within your organization access to the product.	€17861EUR$17,999USD£14,819GBP

Cell Therapy Manufacturing Market (6th Edition): Industry Trends and Global Forecasts to 2035 - Distribution by Type of Cell Therapy, Source of Cells, Scale of Operation, Type of Manufacturer and Geography

Table of Contents

Companies Mentioned (Partial List)

Methodology

Table of Contents

Companies Mentioned (Partial List)

Methodology

Related Topics

Related Reports

Cell Therapy Packaging Market: Industry Trends and Global Forecasts, till 2035 - Distribution by Type of Therapy Packed, Package Engineering Design, Scale of Operation and Key Geographical Regions

Cell and Gene Therapy CRO Market: Industry Trends and Global Forecasts, Till 2035 - Distribution by Type of Cell Therapy, Type of Genetic Modification, Stage of Development, Therapeutic Area, End-users and Key Geographical Regions

CAR-T Cell Therapy Market - Market Size, Forecasts, Trials, and Trends, 2025

Cell Therapy Contract Development And Manufacturing Organization - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2024 - 2029)

CAR T-Cell Therapy for Non-Hodgkin's Lymphoma (NHL) - Market Insight, Epidemiology and Market Forecast - 2032

About the Cell Therapy Manufacturing Market